investor overview – iovance biotherapeutics, inc.
the investor relations website contains information about iovance biotherapeutics, inc.'s business for stockholders, potential investors, and financial analysts.
Total Visits
Avg. Visit Duration
Pages per Visit
Bounce Rate
Registration Date
| Month | Traffic |
|---|---|
| 2025-03 | 7.456 |
| 2025-04 | 5.512 |
| 2025-05 | 9.284 |
| Source | Traffic Share |
|---|---|
| direct | 42.42% |
| search | 30.93% |
| referrals | 18.92% |
| social | 6.74% |
| paid referrals | 0.86% |
| 0.09% |
| Region | Percentage |
|---|---|
| United States | 63.15% |
| United Kingdom | 15.44% |
| China | 7.59% |
| NL | 5.64% |
| Canada | 4.38% |
| Keyword | Traffic | Volume | CPC |
|---|---|---|---|
| amtagvi, is marketed by san carlos-based iovance biotherapeutics. | 4 | 40 | $0.00 |
| fda approves amtagvi | 27 | 270 | $0.00 |